Financials
Financial year 2025
Société Pharmaceutique belge from Sint-Gillis (bij-Brussel), company number BE0403080233, closed financial year 2025 with a result of € 14,170 after tax. For that financial year Société Pharmaceutique belge recorded a gross margin of € 140,706 and equity of € 180,438. Compared with financial year 2024, the result moved from € 8,916 to € 14,170. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 16, 2026.
€ 180,438
▼ 4% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 14,170
▲ 59% vs 2024
Profit after tax over the fiscal year.
€ 189,839
▲ 19% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 21,795 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
1
Average over the fiscal year, from the social balance sheet.
€ 113,074
▲ 6% vs 2024
€ 113,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 56,876
▼ 7% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 32,257
▲ 35% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 146,270 | € 150,016 | € 131,009 | € 140,706 | ▲ 7% |
| Profit after taxes | € 46,758 | € 20,339 | € 8,916 | € 14,170 | ▲ 59% |
| Equity | € 464,893 | € 485,232 | € 188,063 | € 180,438 | ▼ 4% |
| Total debts | € 124,687 | € 87,211 | € 145,366 | € 178,446 | ▲ 23% |
| Cash | € 335,376 | € 320,088 | € 159,731 | € 189,839 | ▲ 19% |
| Land & buildings | € 4,037 | € 4,037 | - | - | |
| Retained profit | € 402,893 | € 423,232 | € 163,933 | € 156,307 | ▼ 5% |
| Dividend | € 27,000 | € 0 | € 0 | € 21,795 | |
| Bank debt | € 0 | € 0 | € 3,877 | € 0 | ▼ 100% |
| Balance sheet total | € 589,579 | € 572,443 | € 333,429 | € 358,883 | ▲ 8% |
| Employees (FTE) | 1.1 | 1 | 1 | 1 |
Key figures of Société Pharmaceutique belge, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Société Pharmaceutique belge?
What happened at Société Pharmaceutique belge in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 14,170 (▲ 59% vs 2024). Source: NBB ↗
- Start of the company according to the CBE. KBO
- New establishment in Sint-Gillis (bij-Brussel). KBO
In short
From € 46,758 profit in 2022 to € 14,170 profit in 2025.
Paid € 27,521 in corporate taxes since 2022.
Best year ever: 2022, with € 46,758 profit.
On average € 140,700 of value added per employee in 2025.
A new publication or filing at Société Pharmaceutique belge? We notify you, reason included.
Follow Société Pharmaceutique belgeDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Société Pharmaceutique belge is CECILE HANCHARD. CECILE HANCHARD is also behind SOPHIMBEL.
Directors
According to the 2025 annual accounts
Establishments
Establishment units
Physical locations of this company
Emile Feronstraat 29
1060 Sint-Gillis (bij-Brussel)
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0403.080.233
- VAT number
- BE 0403.080.233
- Registered office
- Emile Feronstraat 29, 1060 Sint-Gillis (bij-Brussel)
- Names & denominations
- Société Pharmaceutique belge · Sophabel
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 1 January 1968
- Peppol
- Active · Active since 12 Apr 2024
- Activities · NACE
Apothekers
Detailhandel in farmaceutische producten